Evidence map›Paper›PMID 41368235›Full record

ArticleTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2025

Guiding Antiviral Cell Therapy Approaches with an Online Resource of Clinically Scored Epitopes, T-Cell Receptors, and B-Cell Receptors.

Theresa Kaeuferle, Britta Eiz-Vesper, Andreas Moosmann, Uta Behrends, Michel Decker, Lilli Gutjahr, Josef Mautner, Florian Klein, Christoph Kreer, Mira Reger and 7 more

Abstract read
In one paragraph

Article in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Theresa KaeuferleCenter for Cell and Gene Therapy Freiburg, University Medical Center Freiburg, Freiburg, Germany.
Britta Eiz-VesperInstitute of Transfusion Medicine and Transplant Engineering, Hannover Medical School, Hannover, Germany.
Andreas MoosmannGerman Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
Uta BehrendsGerman Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
Michel DeckerDepartment of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
Lilli GutjahrDepartment of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, LMU Klinikum, Dr. von Hauner University Children's Hospital, Munich, Germany.
Josef MautnerGerman Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
Florian KleinLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Christoph KreerLaboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany.
Mira RegerDepartment of Pediatric Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, LMU Klinikum, Dr. von Hauner University Children's Hospital, Munich, Germany.
Dirk H BuschGerman Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
Elvira D'IppolitoGerman Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.
Florian KohlmayerBitcare GmbH, Munich, Germany.
Amrei MenzelBitcare GmbH, Munich, Germany.
Semjon WillierDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University Medical Center Freiburg, Freiburg, Germany.
Britta Maecker-KolhoffGerman Center for Infection Research (DZIF), Partner site Hannover-Braunschweig, Braunschweig, Germany.
Tobias FeuchtingerGerman Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The clinical application of cell-based immunotherapies is a rapidly emerging field, and recent advances in gene therapy have opened up a new era of innovative treatment approaches. Introducing a specific T-cell receptor (TCR) against viral epitopes or chimeric antigen receptor (CAR) into T cells and effector cells allows reprogramming of their specificity and utilization for advanced therapeutic applications in infectious diseases and virus-induced malignancies. Many technologies have been developed to genetically engineer T cells, and existing databases in silico predict or describe identified viral epitopes, TCRs, or B-cell receptors (BCRs). However, their therapeutic application is still hampered by limited knowledge on their clinical impact. Methods: An open-access online resource was developed, integrating a data-mining algorithm scoring the epitopes, TCRs, and BCRs (ETB database) according to clinical evidence. Results: We hereby present a new level of clinical evidence-based knowledge transfer for selecting individual protective TCRs or BCRs for therapeutic application. The database is publicly available at https://app.bitcare.de/epitopeFrontend/. Conclusion: Redirecting T-cell specificity by genetic engineering using clinically protective TCR or CAR sequences will not only bring significant progress to the field of adoptive T-cell therapies but also lay the groundwork for broader applications such as off-the-shelf approaches.

Indexed as

Adoptive T-cell transferAntibodiesAntigensB-cell receptorEpitopeImmune responseInfectionsMHCT-cell receptorT cells

Identifiers

PMID41368235
PMCPMC12685349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.